Couverture de vivian-creativebios' Podcast

vivian-creativebios' Podcast

vivian-creativebios' Podcast

De : Shaw Vivian
Écouter gratuitement

3 mois pour 0,99 €/mois Offre valable jusqu'au 12 décembre 2025. 3 mois pour 0,99 €/mois, puis 9,95 €/mois. Offre soumise à conditions.J'en profite

À propos de ce contenu audio

 An introduction to live biotherapeutics, what is it? How FDA defines it? What is its potential in drug discovery, etc.Copyright 2023 Shaw Vivian Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Episode 6: Next-generation sequencing (NGS)

      Episode 6: Next-generation sequencing (NGS)
      Jun 19 2023
      Personalized medicine is a rapidly evolving health-care industry, in which an individual’s genetic profile is used to customize health management. Explosive advances in next-generation sequencing (NGS) and computational analyses have enabled the evaluation for prevention and early detection of cancers. With years of research and development experience in the field of NGS, Creative Biolabs has established an advanced SuPrecision™ platform to offer an accurate and high-throughput sequencing service to support cancer diagnosis and precision medicine.
      Afficher plus Afficher moins
      9 min
    • Episode 5: Therapeutic Human Monoclonal Antibodies from SARS-CoV-2 Surface Protein - Creative Biolabs

      Episode 5: Therapeutic Human Monoclonal Antibodies from SARS-CoV-2 Surface Protein - Creative Biolabs
      Nov 2 2022
      Monoclonal antibodies are the most important type of biotechnological products after vaccines and recombinant proteins. They are the strategic commanding heights of biotechnology and biomedicine industries in the 21st century. After 35 years of development, monoclonal antibody technology has gone through four stages: murine, chimeric, humanized, and fully human monoclonal antibodies. In response to the COVID-19 outbreak, Creative Biolabs can provide the service of immunizing humanized antibody mice with SARS-CoV-2 surface protein to screen for therapeutic human monoclonal antibodies.
      Afficher plus Afficher moins
      13 min
    • Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2

      Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2
      Oct 7 2022
      VLPs are multi-protein structures, which mimic the organization and conformation of authentic native viruses, but lack the viral genome, and may produce safer and cheaper vaccine candidates. If the specific native viral proteins with immunosuppressive function are excluded from VLPs, the efficacy of these particles can be significantly enhanced. Compared with single protein or peptide, VLPs present more similar conformational epitopes to the original virus. Therefore, antibody reactivity or immune system response is expected to be significantly improved. Due to their highly repetitive surfaces, VLPs are able to induce strong B cell responses without adjuvants by effectively crosslinking specific receptors on B cells. Studies have shown that VLP vaccines can stimulate humoral and cellular immune responses, thus providing effective antiviral protection.
      Afficher plus Afficher moins
      Moins d'une minute
    Aucun commentaire pour le moment